Cognition and violent behavior in psychotic disorders: A nationwide case-control study.
Aggression
Executive functions
Psychosis
Schizophrenia
Theory of mind
Violence
Journal
Schizophrenia research. Cognition
ISSN: 2215-0013
Titre abrégé: Schizophr Res Cogn
Pays: United States
ID NLM: 101632223
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
24
06
2019
revised:
20
09
2019
accepted:
26
09
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
14
12
2019
Statut:
epublish
Résumé
The excess risk of violence in psychotic disorders may partly be explained by impairments in executive functions (EFs) and theory of mind (ToM). However, previous studies have been limited by composite measures of EFs and small samples of inpatients. Data were collected for the research project Genetic Risk and Outcome of Psychosis (GROUP). Patients with psychotic disorders ( Violent patients performed significantly worse than nonviolent patients on the WAIS-III Block Design subtest ( Impairments in EFs and ToM are unlikely to provide useful targets for risk assessment and interventions.
Sections du résumé
BACKGROUND
BACKGROUND
The excess risk of violence in psychotic disorders may partly be explained by impairments in executive functions (EFs) and theory of mind (ToM). However, previous studies have been limited by composite measures of EFs and small samples of inpatients.
METHODS
METHODS
Data were collected for the research project Genetic Risk and Outcome of Psychosis (GROUP). Patients with psychotic disorders (
RESULTS
RESULTS
Violent patients performed significantly worse than nonviolent patients on the WAIS-III Block Design subtest (
CONCLUSION
CONCLUSIONS
Impairments in EFs and ToM are unlikely to provide useful targets for risk assessment and interventions.
Identifiants
pubmed: 31832346
doi: 10.1016/j.scog.2019.100166
pii: S2215-0013(19)30015-0
pii: 100166
pmc: PMC6890945
mid: EMS85709
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100166Subventions
Organisme : Wellcome Trust
ID : 202836
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202836/Z/16/Z
Pays : United Kingdom
Informations de copyright
© 2019 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Schizophr Res. 2006 Jan 31;81(2-3):227-38
pubmed: 16260120
Schizophr Bull. 2019 May 31;:null
pubmed: 31150553
Eur Arch Psychiatry Clin Neurosci. 2011 Apr;261(3):195-203
pubmed: 21086134
Int J Methods Psychiatr Res. 2012 Sep;21(3):205-21
pubmed: 22419500
Dialogues Clin Neurosci. 2010;12(3):383-92
pubmed: 20954432
Schizophr Res. 2004 Jun 1;68(2-3):271-81
pubmed: 15099609
Br J Psychiatry. 2008 Sep;193(3):247-53
pubmed: 18757987
Schizophr Bull. 2016 Jul;42(4):963-74
pubmed: 26895845
Schizophr Res. 2005 Apr 1;74(1):1-13
pubmed: 15694749
Schizophr Bull. 2011 Sep;37(5):899-912
pubmed: 21860036
Biol Psychiatry. 2004 May 15;55(10):1013-22
pubmed: 15121486
Can J Psychiatry. 2017 Feb;62(2):86-93
pubmed: 27605579
Dev Psychopathol. 2009 Fall;21(4):1355-81
pubmed: 19825272
Schizophr Res. 2004 Jul 1;69(1):45-53
pubmed: 15145470
Neuropsychol Rehabil. 2017 Jul;27(5):599-602
pubmed: 28480821
Lancet Psychiatry. 2014 Jun;1(1):44-54
pubmed: 25110636
Int J Neuropsychopharmacol. 2016 Jun 8;:null
pubmed: 27231256
Annu Rev Psychol. 2013;64:135-68
pubmed: 23020641
CNS Drugs. 2013 May;27(5):335-43
pubmed: 23533009
Mol Psychiatry. 2016 Sep;21(9):1251-6
pubmed: 26666206
Psychol Med. 2017 Jul;47(10):1784-1793
pubmed: 28173890
Drug Alcohol Rev. 2013 Jan;32(1):11-8
pubmed: 22672631
Schizophr Res. 1995 Sep;17(1):5-13
pubmed: 8541250
World Psychiatry. 2008 Feb;7(1):22-8
pubmed: 18458774
PLoS One. 2013;8(2):e55942
pubmed: 23418482
Psychopharmacol Bull. 1992;28(4):353-66
pubmed: 1363583
PLoS Med. 2009 Aug;6(8):e1000120
pubmed: 19668362
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Schizophr Bull. 2014 May;40(3):602-16
pubmed: 23686020
Schizophr Res. 2010 Jul;120(1-3):234-5
pubmed: 20067856
Psychiatry Res. 2015 Jan 30;225(1-2):169-174
pubmed: 25467703
Br J Psychiatry. 2007 Jul;191:5-13
pubmed: 17602119
Soc Cogn Affect Neurosci. 2008 Sep;3(3):204-17
pubmed: 19015112
J Psychiatr Res. 2001 Mar-Apr;35(2):119-25
pubmed: 11377441
JAMA Psychiatry. 2013 Oct;70(10):1107-12
pubmed: 23925787
Schizophr Res. 2005 Nov 15;79(2-3):231-8
pubmed: 15982856
Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18
pubmed: 24167693
Schizophr Res. 2015 Feb;161(2-3):478-83
pubmed: 25510926
Schizophr Bull. 1984;10(2):160-203
pubmed: 6729409
Schizophr Res. 2004 Jun 1;68(2-3):319-29
pubmed: 15099613
Neurobiol Dis. 2013 May;53:18-25
pubmed: 23123218
J Exp Psychol Gen. 2004 Mar;133(1):101-135
pubmed: 14979754
Schizophr Res. 2011 Feb;125(2-3):143-51
pubmed: 21112743
Cortex. 2010 May;46(5):668-77
pubmed: 19501818
J Clin Psychiatry. 2005 Mar;66(3):300-8
pubmed: 15766295
Schizophr Res. 2006 Sep;86(1-3):54-70
pubmed: 16837168
Aggress Behav. 2007 Sep-Oct;33(5):412-21
pubmed: 17683105
Lancet. 2014 Sep 27;384(9949):1206-14
pubmed: 24816046
Scientifica (Cairo). 2012;2012:158646
pubmed: 24278673
Psychol Bull. 2007 Sep;133(5):833-58
pubmed: 17723032
Schizophr Bull. 1995;21(2):253-62
pubmed: 7631172
Nat Rev Neurosci. 2015 May;16(5):290-304
pubmed: 25891510
Psychol Aging. 2013 Sep;28(3):826-39
pubmed: 23276217
Schizophr Res. 2011 Feb;125(2-3):209-20
pubmed: 21208783
Schizophr Res. 2000 Mar 16;42(1):67-77
pubmed: 10706987
Schizophr Res. 1999 May 25;37(2):183-90
pubmed: 10374653
J Clin Exp Neuropsychol. 2008 Aug;30(6):700-9
pubmed: 18608673
Neuropsychobiology. 2013;68(3):139-45
pubmed: 24051542